SCHEMBL6709079

SCHEMBL6709079

Cc1n[nH]c(-c2ccccc2Cl)c1C(=O)Nc1ccc2c(c1)OCO2

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 13/20 0.59
NPC1 O15118 12/20 0.59
MEN1 O00255 5/20 0.59
KMT2A Q03164 5/20 0.59
CYP1A2 P05177 1/20 0.56
CYP3A4 P08684 1/20 0.56
CYP2D6 P10635 1/20 0.56
CYP2C9 P11712 1/20 0.56
CYP2C19 P33261 1/20 0.56
TOP1 P11387 1/20 0.54
PTGS2 P35354 1/20 0.54
MAPT P10636 5/20 0.53
LMNA P02545 1/20 0.53
TP53 P04637 3/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
HSP90AA1 P07900 1/20 0.52
HSP90AB1 P08238 1/20 0.52
HPGD P15428 2/20 0.51
CASP3 P42574 2/20 0.51
SENP7 Q9BQF6 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6707272 0.88 RAB9A (0.46) RAB9ANPC1MEN1KMT2ACYP1A2
SCHEMBL6710654 0.85 RAB9A (0.56) RAB9ANPC1MEN1KMT2ACYP1A2
SCHEMBL6709187 0.81 NPC1 (0.66) RAB9ANPC1MEN1KMT2ACYP1A2
SCHEMBL6709083 0.81 ALDH1A1 (0.60) RAB9ANPC1MEN1KMT2AMAPT
SCHEMBL6712450 0.78 EPAS1 (0.47) RAB9ANPC1MEN1KMT2ACYP1A2
SCHEMBL6710635 0.78 EPAS1 (0.45) RAB9ANPC1MEN1KMT2AMAPT
SCHEMBL6707268 0.77 EPAS1 (0.50) RAB9ANPC1MEN1KMT2AMAPT
SCHEMBL29058671 0.77 EPAS1 (0.63) RAB9ANPC1LMNATP53SMN1; SMN2
SCHEMBL29059208 0.77 EPAS1 (0.66) MEN1KMT2AMAPTLMNASMN1; SMN2
SCHEMBL6709199 0.74 RAB9A (0.44) RAB9ANPC1MEN1KMT2ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040102489-A1 Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders SUGEN, INC. 2004-05-27 US disclosed
US-6649635-B2 For therapy of cancer SUGEN, INC. 2003-11-18 US disclosed
US-20020065283-A1 Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders MCMAHON GERALD (US) 2002-05-30 US disclosed
EP-1012150-A4 HETEROARYLCARBOXAMIDE COMPOUNDS ACTIVE AGAINST PROTEIN TYROSINE KINASE RELATED DISORDERS SUGEN INC (US) 2002-05-29 EP disclosed
US-6316479-B1 ANTICANCER AGENTS SUGEN, INC. 2001-11-13 US disclosed
EP-1012150-A1 HETEROARYLCARBOXAMIDE COMPOUNDS ACTIVE AGAINST PROTEIN TYROSINE KINASE RELATED DISORDERS Sugen, Inc. (US) 2000-06-28 EP disclosed
WO-1998052944-A1 HETEROARYLCARBOXAMIDE COMPOUNDS ACTIVE AGAINST PROTEIN TYROSINE KINASE RELATED DISORDERS SUGEN, INC. (US) 1998-11-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020065283-A1 Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders ABL1, ERBB2, PRKDC RAB9A 1132/4885NPC1 2134/4885MEN1 3182/4885
US-20040102489-A1 Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders ABL1, ERBB2, PRKDC RAB9A 1132/4885NPC1 2134/4885MEN1 3182/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.